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McCune-Albright  syndrome  (MAS)  is  a  rare  disorder  that  develops  from  an  activating  mutation  in  the  Gs  gene.  It 
is  characterized  by  an  association  with  Polyostotic  fibrous  dysplasia,  and  precocious  puberty,  Caf-au-lait  pigmentation, 
and  other  endocrinopathies  that  result  from  the  hyperactivity  of  a  variety  of  endocrine  glands.  Recently  we  encountered 
a  patient  with  MAS  with  fibrous  dysplasia,  skin  pigmentation,  acromegaly,  hyperprolactinemia  and  a  thyroid  nodule.  A 
23-year-old  male  presented  for  an  evaluation  of  a  change  in  his  facial  structures.  Fibrous  dysplasia  was  diagnosed 
by  a  bone  biopsy  and  radiographic  studies.  The  GH  level  increased  paradoxically  after  an  oral  glucose  load.  The 
plasma  prolactin,  IGF-1  and  alkaline  phosphatase  were  high.  Thyroid  ultrasonography  revealed  multiple  nodules.  The 
brain  MRI  demonstrated  a  mass  in  the  left  pituitary  gland.  Genetic  analysis  identified  a  change  from  Arg  (CGT)  at 
codon  201  to  Cys  (TGT).
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INTRODUCTION 
McCune-Albright  syndrome  (MAS)  is  a  rare  disease  that  was 
originally  defined  by  the  triad  of  polyostotic  fibrous  dysplasia  of 
the  bone  (FD),  caf-au-lait  skin  pigmentation  and  precocious 
puberty
1, 2).  A  number  of  endocrine  disorders  such  as  hyper-
thyroidism,  excess  growth  hormone  (GH),  Cushing  syndrome
3) 
and  rickets/osteomalacia  might  be  associated  with  MAS
3, 4).  The 
disease  results  from  post  zygotic  activating  mutations  of  the 
cAMP  regulating  protein,  GNAS1  gene  product,  and  Gs
5, 6).  Most 
Gs  mutations  are  point  mutations  at  the  Arg201  position,  with 
the  majority  being  Arg201  His  or  Cys
7).  Recently,  weevaluated  a 
23-year-old  man  with  typical  MAS  who  had  FD,  skin 
pigmentation  and  multiple  endocrinopathies  including  acromegaly, 
hyperprolactinemia  and  a  thyroid  nodule.  Genetic  analysis 
confirmed  a  point  mutation  of  the  GNAS1  gene.  We  report  this 
case  with  a  review  of  the  relevant  literature.
CASE REPORT
A  23  year-old  man  was  referred  to  our  hospital  for  an 
evaluation  of  a  change  in  his  facial  structures  that  started  from 
the  age  of  17  years.  His  facial  features  gradually  coarsened, 
and  his  nose  was  deviated  to  the  right  side.  He  experienced  a 
progressive  increase  in  height  with  the  growth  of  his  hands  and 
feet,  and  had  thick  fingers  and  toes  for  the  last  six  to  seven 
years.  He  was  recently  diagnosed  at  a  local  clinic  with  diabetes 
mellitus  and  had  been  treated  with  oral  glimepiride  (1  mg/day). 
In  addition,  he  had  visual  problems  that  were  diagnosed  when 
he  was  eight  as  well  as  FD  diagnosed  by  a  bone  biopsy  in 
another  hospital.  He  had  undergone  maxillary  decompression 
surgery  and  had  a  history  of  femur  fractures  after  trauma.  His 
father  died  at  a  young  age  and  his  mother  had  diabetes  mellitus 
and  visual  loss. 
A  physical  examination  revealed  that  his  height,  weight  and The  Korean  Journal  of  Internal  Medicine  :  Vol.  22,  No.  1,  March  2007 46
Time  (min) Basal 60 120 180 240 300 360
Somatostatin GH  (ng/mL) 44.3 11.6 9.5 10.0 13.9 21.7 33.9
Bromocriptine
GH  (ng/mL)
Prolactin  (ng/mL)
47.5
55.8
41.7
48.5
18.6
30.7
18.1
19.5
8.3
11.4
8.9
10.7
12.4
11.5
*0.1  mg  of  sandostatin  IV,  2.5  mg  of  Bromocriptine  PO 
GH,  growth  hormone
Table  3.  Somatostatin  and  Bromocriptine  Test* 
Times  (min) Basal 30 60 90 120
ACTH  (pg/mL)
Cortisol  (㎍/dL)
GH  (ng/mL)
LH  (IU/L)
FSH  (IU/L)
TSH  (μIU/mL)
Prolactin  (ng/mL)
18.9
11.2
36.2
3.2
6.2
1.1
61.4
10.4
9.4
102.4
32.1
12.6
13.2
111.6
32.8
15.3
68.7
28.6
13.3
8.0
95.7
54.4
14.9
46.4
25.7
13.4
6.5
77.3
29.2
13.8
39.1
28.4
13.1
4.7
69.7
ACTH,  Adrenocorticotropic  hormone;  GH,  growth  hormone;  LH,  Luteinizing  hormone;  FSH,  Follicle‐stimulating  hormone;  TSH,  thyroid  stimulating 
hormone;  LH,  Luteinizing  hormone 
*  0.1  ㎍  of  regular  insulin,  400  ㎍  of  TRH  and  100  ㎍  of  GnRH  IV. 
Table  2.  Combined  Pituitary  Function  Test* 
Time  (min)  Basal 30 60 90 120
Glucose  (mg/dL)
GH  (ng/mL)
110
34.8
162
47.8
219
48.2
293
46.1
260
43.8
GH,  growth  hormone
Table  1.  75  g-Oral  Glucose  Tolerance  Test 
 
Figure  1.  General  appearance  of  the  23-year-old  patient.  The  aptient  had  mandibular 
prognathism  (A),  and  an  irregular  shaped,  but  not  elevated  black  and  brown  colored 
pigmentation  on  the  back  and  lips  (B).
body  mass  index  were  185  cm,  87  kg  and  27.0  kg/m
2, 
respectively.  The  BP  was  130/80  mmHg.  He  had  mandibular 
prognathism,  maxillomandibular  malocclusion,  and  acral 
enlargement  with  caf-au-lait  pigmentation  on  the  back  and  lips 
(Figure  1A,  1B).  There  were  no  abnormalities  in  his  external 
genitalia.  The  results  of  the  complete  blood  count,  liver  and 
renal  function  test  were  all  normal.  The  fasting  and  two-hour 
whole-blood  glucose  levels  were  162  and  293  mg/dL,
ABFigure 2. X-ray of the skull and tibia shows osteolytic lesions with 
bone  thickening. 
Figure 4. Brain CT scan reveals lesions with bony  thickening and 
a  deformity  at  the  skull  base. 
Figure  3.  Coronal  image  of  a  sellar  MRI  of  the  brain  shows  an 
infiltrative  solid  mass  in  the  left  pituitary  gland  with  a  cavernous 
sinus  extension  encasing  the  carotid  artery. 
Figure 5. Bone scan shows multiple hot spots with uptake at the 
skull,  facial  bone,  ribs,  humerus  and  tibia. 
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respectively.  The  serum  calcium  and  phosphate  levels  were  9 
mg/dL  (8.6-10.3)  and  2.9  mg/dL  (2.5-4.5),  respectively.  The 
iPTH  level,  alkaline  phosphatase  level,  serum  osteocalcin  level 
and  urine  deoxypyridinoline/Creatinine  ratio  was  61.4  pg/mL 
(12-72),  950  IU/L  (75-270),  288.10  ng/mL  (10.3-23.7)  and  37.3 
nM/mM  (2.5-5.5),  respectively.  The  basal  GH  level  was  34.8 
ng/mL,  which  paradoxically  increased  to  48.2  ng/mL  (N<2 
ng/mL)  after  a  75  gm  oral  glucose  load  (Table  1). The  Korean  Journal  of  Internal  Medicine  :  Vol.  22,  No.  1,  March  2007 48
Figure  6.  Thyroid  Ultrosonography  shows  an  ill  defined  solid 
hypoechoic  mass  in  the  left  lobe  of  the  thyroid.
 
Figure  7.  Mutational  analysis  of  the  genomic  DNA  isolated  from  the  thyroid  tissue  using  standard  PCR  amplification  and  direct 
sequencing.  Forward  sequencing  reaction  of  the  genomic  DNA  shows  a  clear  red  T  peak  in  the  wild-type  C  due  to  C-to-T  mutation  at 
R201C  transition  in  the  GNSA1  gene.  (B)  Reverse  sequencing  reaction  of  the  genomic  DNA  also  shows  an  A  peak  under  G.
In  response  to  a  400  ㎍  IV  bolus  thyrotropin  releasing  hormone 
(TRH),  the  GH  level  increased  from  36.2  ng/mL  to  68.7  ng/mL 
(Table  2),  and  the  serum  IGF-1  level  was  1544.2  ng/mL  (100-366). 
The  serum  prolactin  level  was  61.4  ng/mL  (2.1-17.7)  and  the  total 
testosterone  level  was  1.1  ng/mL  (2.4-8.1).  The  level  of  TSH,  total 
T3  and  free  T4  were  3.0  IU/mL  (0.4-4.7),  1.66  ng/mL  (0.6-1.7)  and 
1.1  ng/mL  (0.7-1.9),  respectively.  The  basal  ACTH  and  cortisol 
levels  were  normal  but  the  response  of  ACTH  and  cortisol  was 
diminished  on  the  combined  pituitary  function  test  (Table  2).  The 
level  of  GH  secretion  decreased  when  he  was  administered 
somatostatin  and  bromocriptine,  (Table  3). 
The  X-ray  revealed  that  the  skull  and  facial  bones  had  a 
wavy  thickening  and  deformity.  There  was  a  well-defined 
osteolytic  mass  in  the  left  humerus,  the  distal  portion,  as  well  as 
ground-glass  opacity  inside  of  the  bone.  In  addition,  a  similar 
osteolytic  lesion  was  observed  in  the  right  foot,  both  femurs, 
right  fibula,  right  iliac  bone  and  left  scapula.  In  addition,  there 
was  diffuse  thickening  and  a  deformity  of  the  ribs  (Figure  2). 
The  heel  pad  index  was  24.7  mm.  The  Sellar  MRI  of  the  brain 
revealed  an  infiltrative  solid  mass  (13×8  mm)  in  the  left  pituitary 
gland  extending  into  the  left  cavernous  sinus  with  encasement 
of  the  left  carotid  artery  (Figure  3).  Contrast  enhanced 
computerized  tomography  of  brain  revealed  lesions  with  bony 
thickening  and  a  deformity  at  the  skull  base  (Figure  4).  The 
bone  scan  showed  multiple  hot  spots  with  uptake  at  the  skull, 
facial  bone,  ribs,  humerus  and  tibia  (Figure  5).  Thyroid 
ultrasonography  indicated  multiple  ill  defined  solid  hypoechoic 
nodules  in  both  lobes  of  the  thyroid  (Figure  6).  The  result  of  a 
fine  needle  aspiration  was  adenomatous  hyperplasia. 
Esophagoduodenoscopy  and  colonoscopy  did  not  reveal  any 
abnormalities.  Genetic  analysis  for  a  mutationwas  performed  by 
sequencing  the  polymerase  chain  reaction  (PCR)-amplified 
genomic  DNA.  DNA  was  extracted  from  the  venous  blood, 
pigmented  skin  and  a  thyroid  nodule.  Base  sequencing  was 
carried  out  using  the  sense  (5'-TGACTATGTGCCGAGCGA-3') 
and  antisense  primers  (5'-CCACGTCAAACATGCTGGTG-3'). 
The  mutation  was  identified  only  in  the  thyroid  tissue.  There  was 
a  change  from  Arg  (CGT)  in  codon  201  to  Cys  (TGT)  at  the 
R201C  position  (Figure  7A,  7B).
  The  percentage  of  cells  with  a  mutation  in  GNAS1  out  of 
the  total  number  of  cells  from  each  tissue  was  so  low  that  it 
was  difficult  to  identify  by  direct  base  sequencing.  Therefore, 
mutation  allele  specific  amplification  was  carried  out.  PCR  was 
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Figure  8.  Determination  of  a  GNSA1  mutation  using  mutant  allele 
specific  amplification  shows  that  the  mutant  type  allele  1  was 
detected  in  all  specimens  from  the  patient  including:  blood, 
pigmented  skin  and  thyroid  tissue.  1  and  5,  2  and  6,  3  and  7,  4 
and  8  :  PCR  reactions  with  genomic  DNA  from  blood,  skin  and 
thyroid  tissue  from  the  patient  and  a  negative  control, 
respectively1,2,3,4  :  wild  type  primer,  5,6,7,8  :  mutant  type  primer
completed  after  combining  the  sense  primer  (5'-CCTGCTT 
CGCTGCC-3'),  which  did  not  have  a  mutation  and  was  considered 
to  be  the  wild  type,  and  the  sense  primer  (5'-CCTGCTTCGCTGCT 
-3'),  which  was  the  mutation  type  with  the  antisense  primer 
(5'-GGACTGGGGTCAATGTCAAG-3'),  separately.  As  a  result 
of  the  mutation  allele  specific  amplification,  the  mutant  type 
allele  was  detected  in  the  blood,  pigmented  skin  and  thyroid 
tissue  from  the  affected  patient  (Figure  8).  The  skull  deformity 
was  too  severe  from  FD  to  perform  surgery.  Therefore,  medical 
treatment  with  somatostain  (sandostatin  LAR  30  mg  IM  q 
month)  and  bromocriptine  (Antilactin  7.5  mg  bid  PO)  was 
started.  The  prolactin  level  was  kept  within  normal  limits,  and 
the  GH  and  IGF-1  levels  had  a  tendency  to  decrease  (GH  5.9 
ng/mL,  IGF-1  786  ng/mL).  The  FD  of  the  bone  is  under 
observation  and  Pamidronate  treatment  is  being  considered. 
DISCUSSION 
Typical  MAS  is  characterized  by  FD  with  at  least  one  of  the 
typical  hyperfunctioning  endocrinopathies  along  with  caf-au-lait 
spots.  Unlike  a  typical  case  of  MAS,  patients  with  FD  and  more 
than  two  endocrine  disorders  without  skin  pigmentation  or 
precocious  puberty  are  defined  as  having  atypical  MAS
8). 
Although  typical  MAS  is  relatively  rare,  FD  of  the  bone  not 
associated  with  either  skin  pigmentation  or  endocrine 
disturbances  is  a  frequent  and  usually  serious  skeletal  disorder
9).
Only  three  cases  of  typical  or  atypical  MAS  have  been 
reported  in  Korea
10-12).  Bony  fibrous  dysplasia  most  commonly 
occurs  in  the  proximal  femur  and  at  the  base  of  the  skull.  FD 
of  the  skeleton  usually  presents  with  a  limp  or  pain  but 
occasionally  a  pathologic  fracture  may  be  the  presenting  sign. 
FD  of  the  craniofacial  bones  can  cause  visual  disturbances, 
proptosis,  nasal  obstructions,  facial  asymmetry  or  hearing 
abnormalities.
The  endocrine  disorders  accompanying  MAS  are  precocious 
puberty,  pituitary  adenomas  secreting  growth  hormone  and/or 
prolactin,  Cushing  syndrome,  hypophosphatemic  osteomalacia, 
thyroid  abnormalities  (hyperthyroidism  and  benign  and  malignant 
thyroid  nodule)  and  hyperparathyroidism
3, 4, 13).  Growth  hormone 
hypersecretion  in  MAS  is  common  but  differs  from  that 
observed  in  classic  acromegaly  in  several  aspects.  Patients  are 
generally  young  at  onset  and  are  diagnosed  based  on  the 
observation  of  growth  acceleration  rather  than  from  the  facial 
dysmorphism,  which  is  usually  difficult  to  assess  due  to  fibrous 
dysplasia
14).  MAS  with  a  GH  excess  has  a  distinct  clinical 
phenotype  that  is  characterized  by  the  TRH  responsiveness, 
prolactin  co-secretion,  small  or  absent  pituitary  tumors,  a 
consistent  but  inadequate  response  to  a  treatment  with 
cabergoline,  and  an  intermediate  response  to  sandostatin  LAR. 
Vision  and  hearing  deficits  are  more  common  in  MAS  with  an 
excess  of  GH  than  in  those  without  an  excess.  Patients  with 
precocious  puberty  and  an  excess  of  GH  have  achieved  a 
normal  adult  height  despite  a  history  of  early  epiphyseal  fusion.
MAS  syndrome  is  the  result  of  an  activating  mutation  of  the 
alpha  subunit  of  the  Gs  protein  (GNAS1  gene),  which  causes 
the  constitutive  activation  of  adenylate  cyclase.  In  all  published 
cases  of  MAS,  mutations  of  GS  at  the  R201  position  have  been 
identified
9).  The  unproven  but  accepted  explanation  for  the  lack 
of  vertical  transmission,  along  with  the  observation  that  the  skin 
and  bone  lesions  tend  to  lateralize,  is  that  the  disease  results 
from  postzygotic  mutations.  Hence,  the  patients  are  referred  to 
as  somatic  mosaics.  The  mosaicism  could  explain  the  varied 
clinical  picture  of  those  with  this  syndrome
5).  The  percentage  of 
cells  with  the  GNAS1  mutation  out  of  a  total  number  of  cells  in 
each  tissue  might  be  very  low  due  to  the  mosaicism.  This 
explains  why  GS  mutations  at  the  R201  position  are  detected 
only  in  the  thyroid  tissue  by  direct  base  sequencing,  as  in  our 
case.  However,  the  detection  of  a  mutation  in  all  samples  was 
obtained  after  using  the  mutation  allele  specific  amplification 
method.  FD  presents  a  treatment  dilemma  because  there  is  no 
proven  medical  therapy.  Bisphosphates  have  been  shown  to 
reduce  the  incidence  of  fractures  and  reduce  the  intensity  of 
bone  pain.  However,  the  only  cure  for  FD  is  a  surgical 
resection,  which  is  difficult  in  the  skull  and  facial  regions. 
Surgery  is  recommended  when  there  is  a  functional  cranial 
nerve  deficit  in  order  to  prevent  or  limit  the  permanent  loss  of 
function
15).  Medical  treatment  using  a  somatostatin  or  dopamine 
agonist  is  often  the  only  option  in  patients  with  MAS  and  an 
excess  of  GH  because  transsphenoidal  surgery  is  not  possible 
due  to  the  massive  thickening  of  the  skull  base  with  FD
14, 16, 17). 
Radiation  therapy  is  not  considered  to  be  an  option  because  it  is 
believed  to  predispose  FD  to  a  sarcomatous  transformation
18, 19). 
Hyperthyroidism  in  a  MAS  setting  is  treated  with  the  same 
medication  options  used  for  treating  hyperthyroidism
4).
Wepresent  a  case  of  Typical  MAS  with  FD,  skin  pigmentation, 
acromegaly,  hyperprolactinemia,  and  a  thyroid  nodule  in  a 
23-year-old  man. The  Korean  Journal  of  Internal  Medicine  :  Vol.  22,  No.  1,  March  2007 50
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